The Next Ozempic Will Rewrite Human Performance
A new class of weight loss drugs has already reshaped how people think about fat loss, but retatrutide is positioning itself as something bigger. Not just another GLP 1, but a step toward full scale metabolic control.
Currently in Phase III clinical trials, retatrutide is a triple agonist, meaning it targets three key metabolic pathways at once, GLP 1, GIP, and glucagon. That matters. Instead of simply suppressing appetite like earlier drugs, it appears to increase energy expenditure, improve fat metabolism, and sustain significant weight loss over time. (PMC)
The numbers are what’s driving the attention. In earlier trials, participants lost between roughly 22 to nearly 30 percent of their body weight over about a year, results that rival or even exceed some bariatric procedures. (GQ) More recent late stage data continues to show dramatic reductions, with some participants losing close to 29 percent of total body weight. (Verywell Health)
Excerpted from Men’s Health
